Guest EditorialHealth Equity To make clinical trials equitable, cancer groups evaluate restrictive eligibility criteria November 19, 2021Vol.47 No.43By Julia Beaver, Thomas S. Uldrick, Gwynn Ison, Suanna S. Bruinooge, Caroline Schenkel and Edward S. Kim
Cancer History ProjectConversation with The Cancer LetterFree Patricia Ganz on how survivorship went from being an outlier to the mainstream November 19, 2021Vol.47 No.43By Alexandria Carolan
FreeIn the Archives Cancer researchers, including Nobel laureates, center directors, gather at Nixon Library to mark 50th anniversary of the National Cancer Act November 19, 2021Vol.47 No.43
FreeHealth Equity Project Equity: FDA considers options to increase diverse enrollment in clinical trials November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Conversation with The Cancer LetterFreeHealth Equity FDA’s Lola Fashoyin-Aje: Stop getting stuck on the “risks” of diversity in drug development, it’s time to fix disparities in access November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Conversation with The Cancer LetterFreeHealth Equity NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Capitol Hill ARPA-H, the key element of Biden cancer agenda, faces uncertain future November 12, 2021Vol.47 No.42By Alice Tracey
FreeObituary Walter Lawrence, cancer surgeon and civil rights hero, dies at 96 November 12, 2021Vol.47 No.42By Robert A. Winn and Gordon D. Ginder
FreeIn the Archives The National Cancer Act pioneers: The Roswell Park hearings and VCU Massey’s Walter Lawrence November 12, 2021Vol.47 No.42
Trials & Tribulations Approval of an immunotherapy for adjuvant NSCLC indication gives us new reasons for finding early-stage disease November 12, 2021Vol.47 No.42By Fred R. Hirsch
